arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

ClearPoint Neuro, Inc.

CLPT
$14.99 ▼ -0.81 (-5.13%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
65 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
17
Health
Poor
Bearish
auto_awesome

Analytical Summary

ClearPoint Neuro, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $452.2M
Dividend Yield
Revenue Growth 18.1%
Op. Margin -94.2%
ROIC -16.7%
FCF / Share $-0.24
Trailing P/E
Price / Book 42.4x
FCF Yield
Debt / Equity 4.66
info Valuation on last close. End-of-day price, Sep 23, 2026.

65-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$10.88M
↑ +18.1%
Net Income Profit after all expenses
$-9.55M
↓ -58.5%
Operating Margin Operating profit as % of sales
-94.2%
↓ -34.7% 4th
FCF / Share Free cash flow per share
$-0.24
↑ +17.8%
Long-Term Debt Long-term obligations
$50.23M
↑ +1.2%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
4
Returns
10
Financial Health
18
Cash Quality
63

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 17 years · 65 quarters